HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib

[1]  John R. Mackey,et al.  Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study. , 2009 .

[2]  C. Streuli,et al.  Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer , 2009, Breast Cancer Research.

[3]  S. Loibl,et al.  Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  H. Burstein,et al.  Neratinib (HKI-272), an irreversible pan erbB receptor tyrosine kinase inhibitor: phase 2 results in patients with advanced HER2+ breast cancer. , 2009 .

[5]  M. Hung,et al.  Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer. , 2008, Cancer research.

[6]  C. Hudis,et al.  Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Keith L. Ligon,et al.  Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies , 2007, Science.

[8]  J. Isola,et al.  Trastuzumab causes antibody-dependent cellular cytotoxicity–mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance , 2007, Molecular Cancer Therapeutics.

[9]  F. Montemurro,et al.  Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  F. Montemurro,et al.  Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity , 2007, Expert opinion on biological therapy.

[11]  M. Berger,et al.  Lapatinib plus capecitabine for HER2-positive advanced breast cancer. , 2006, The New England journal of medicine.

[12]  F. Yu,et al.  Stable RNA interference of ErbB-2 gene synergistic with epirubicin suppresses breast cancer growth in vitro and in vivo. , 2006, Biochemical and biophysical research communications.

[13]  P. Hegde,et al.  A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[14]  J. Carlsson,et al.  Effects of HER2-Binding Affibody Molecules on Intracellular Signaling Pathways , 2006, Tumor Biology.

[15]  Jorma Isola,et al.  Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. , 2006, The New England journal of medicine.

[16]  E. Henson,et al.  Herceptin Sensitizes ErbB2–Overexpressing Cells to Apoptosis by Reducing Antiapoptotic Mcl-1 Expression , 2006, Clinical Cancer Research.

[17]  M. A. Hardwicke,et al.  Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers. , 2006, Cancer research.

[18]  Ryuji Kobayashi,et al.  Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. , 2005, Cancer research.

[19]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[20]  G. Gores,et al.  The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006 , 2005, Oncogene.

[21]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[22]  David Grimes,et al.  Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  C. Tacchetti,et al.  TGFα expression impairs Trastuzumab-induced HER2 downregulation , 2005, Oncogene.

[24]  J. Isola,et al.  Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. , 2005, Cancer research.

[25]  C. Arteaga,et al.  Mechanisms of resistance development against trastuzumab (Herceptin) in an in vivo breast cancer model. , 2004, International journal of clinical pharmacology and therapeutics.

[26]  Ming Tan,et al.  PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. , 2004, Cancer cell.

[27]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[28]  D. Slamon,et al.  Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. , 2001, Seminars in oncology.

[29]  W. Piacibello,et al.  The involvement of human-nuc gene in polyploidization of K562 cell line. , 2000, Experimental hematology.

[30]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[31]  E. Perez,et al.  Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.